News 11.06.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics and Orano Med, a clinical stage...
Events, External events
Event date: 26.06.2024
Join Clarivate on June 26th at 4 pm CEST to explore "Informed Risk Assessment: Leveraging Preclinical Safety Intelligence to anticipate Clinical Adverse Events." Discover how OFF-X's tools mitigate risks in drug development, focusing on Semagacestat, BTK inhibitors, and 4-1BB activators. Enhance patient safety and streamline your development process with valuable insights...
News 06.06.2024 Zurich, Switzerland – June 05, 2024 Microcaps AG, a leading innovator in advanced microencapsulation technology, today announced the successful completion of its Series A financing round, raising CHF 9.3 million. This significant capital increase marks a pivotal moment for the company as it aims to meet the growing demand for its...
News 06.06.2024 Topadur Pharma AG and Oshen Holdings SA have signed an agreement to develop the liquid topical formulation of TOP-M119 for treating alopecia. The contract covers co-development, licensing and commercialisation rights for Greater China, focusing initially on completing the IND studies and clinical phases I and II. The deal is based...
News 03.06.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today announced it...